NASDAQ:MYGN Myriad Genetics - MYGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $23.23 +0.70 (+3.11%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$22.82▼$23.4450-Day Range$18.18▼$23.7552-Week Range$13.92▼$28.18Volume582,596 shsAverage Volume697,924 shsMarket Capitalization$1.89 billionP/E RatioN/ADividend YieldN/APrice Target$26.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Myriad Genetics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside12.8% Upside$26.20 Price TargetShort InterestBearish6.39% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.32Based on 5 Articles This WeekInsider TradingSelling Shares$351,429 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.71) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector830th out of 1,004 stocksDiagnostic Substances Industry10th out of 14 stocks 2.0 Analyst's Opinion Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.20, Myriad Genetics has a forecasted upside of 12.8% from its current price of $23.23.Amount of Analyst CoverageMyriad Genetics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.39% of the outstanding shares of Myriad Genetics have been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Myriad Genetics has recently increased by 15.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMyriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Myriad Genetics is -0.60. Previous Next 2.4 News and Social Media Coverage News SentimentMyriad Genetics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Myriad Genetics this week, compared to 2 articles on an average week.Search Interest6 people have searched for MYGN on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $351,429.00 in company stock.Percentage Held by InsidersOnly 1.80% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.08% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.71) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -16.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -16.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Myriad Genetics (NASDAQ:MYGN) StockMyriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.Read More Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address MYGN Stock News HeadlinesMarch 31, 2023 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) COO Nicole Lambert Sells 6,433 SharesMarch 16, 2023 | thestreet.comWill Myriad Genetics (MYGN) Stock React to Price Target Cut at Jefferies?April 1, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 3, 2023 | finance.yahoo.comMyriad Genetics, Inc. (NASDAQ:MYGN) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | finanznachrichten.deMyriad Genetics, Inc.: Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United StatesMarch 2, 2023 | finance.yahoo.comIllumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United StatesMarch 1, 2023 | finance.yahoo.comMyriad Genetics (MYGN) Q4 Earnings Top, Gross Margin FallsMarch 1, 2023 | finance.yahoo.comMyriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue EstimatesApril 1, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 1, 2023 | finance.yahoo.comMyriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGCMarch 1, 2023 | finance.yahoo.comQ4 2022 Myriad Genetics Inc Earnings CallFebruary 28, 2023 | markets.businessinsider.comMyriad Genetics Inc. Q4 Loss Increases, but beats estimatesFebruary 28, 2023 | msn.comMyriad Genetics Non-GAAP EPS of -$0.12 beats by $0.05, revenue of $177.8M beats by $8.38MFebruary 28, 2023 | finance.yahoo.comMyriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® VolumesFebruary 27, 2023 | msn.comEarnings Preview For Myriad GeneticsFebruary 23, 2023 | seekingalpha.comMYGN Myriad Genetics, Inc.February 22, 2023 | finance.yahoo.comMyriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023February 21, 2023 | uk.finance.yahoo.comMyriad Genetics, Inc. (MYGN)February 18, 2023 | marketwatch.comAncestry Testing Market by Manufacturers like 23andMe, MyHeritage, LabCorp, Myriad GeneticsFebruary 9, 2023 | finance.yahoo.comMyriad Genetics to Participate in Upcoming Healthcare ConferencesJanuary 18, 2023 | seekingalpha.comNatera, Myriad upgraded as Raymond James reviews genetic testing spaceJanuary 18, 2023 | finance.yahoo.comRaymond James Upgrades Natera & Myriad Genetics, While Downgrading This StockJanuary 10, 2023 | finance.yahoo.comMyriad Genetics (MYGN) Ailed by Mounting Costs, FX HeadwindJanuary 5, 2023 | finance.yahoo.comMyriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal AbnormalitiesJanuary 4, 2023 | finance.yahoo.comMyriad Genetics to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2023 | finance.yahoo.comMyriad Genetics to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 25, 2022 | thestreet.comMyriad Genetics (MYGN) Shows Signs Of Being Water-Logged And Getting WetterSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address MYGN Company Calendar Last Earnings11/02/2021Today4/01/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MYGN CUSIP62855J10 CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,600Year Founded1991Price Target and Rating Average Stock Price Forecast$26.20 High Stock Price Forecast$32.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+12.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,000,000.00 Net Margins-16.51% Pretax Margin-20.73% Return on Equity-5.83% Return on Assets-4.42% Debt Debt-to-Equity RatioN/A Current Ratio2.00 Quick Ratio1.85 Sales & Book Value Annual Sales$678.40 million Price / Sales2.78 Cash Flow$0.19 per share Price / Cash Flow121.67 Book Value$10.93 per share Price / Book2.13Miscellaneous Outstanding Shares81,220,000Free Float79,762,000Market Cap$1.89 billion OptionableOptionable Beta1.82 Social Links Key ExecutivesPaul J. DiazPresident, Chief Executive Officer & DirectorNicole LambertChief Operating OfficerR. Bryan RiggsbeeChief Financial Officer, Treasurer & Executive VPDale MuzzeyChief Scientific OfficerKevin R. HaasChief Technology OfficerKey CompetitorsCelldex TherapeuticsNASDAQ:CLDXHeskaNASDAQ:HSKAIntellia TherapeuticsNASDAQ:NTLANeogenNASDAQ:NEOGLantheusNASDAQ:LNTHView All CompetitorsInsiders & InstitutionsNicole LambertSold 6,433 sharesTotal: $151,046.84 ($23.48/share)Voya Investment Management LLCSold 10,443 shares on 2/28/2023Ownership: 0.066%NatixisBought 3,041 shares on 2/24/2023Ownership: 0.004%Teachers Retirement System of The State of KentuckyBought 3,067 shares on 2/22/2023Ownership: 0.030%Macquarie Group Ltd.Sold 784 shares on 2/21/2023Ownership: 0.167%View All Insider TransactionsView All Institutional Transactions MYGN Stock - Frequently Asked Questions Should I buy or sell Myriad Genetics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares. View MYGN analyst ratings or view top-rated stocks. What is Myriad Genetics' stock price forecast for 2023? 4 analysts have issued 1-year price objectives for Myriad Genetics' stock. Their MYGN share price forecasts range from $23.00 to $32.00. On average, they predict the company's stock price to reach $26.20 in the next year. This suggests a possible upside of 12.8% from the stock's current price. View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts. How have MYGN shares performed in 2023? Myriad Genetics' stock was trading at $14.51 at the start of the year. Since then, MYGN shares have increased by 60.1% and is now trading at $23.23. View the best growth stocks for 2023 here. When is Myriad Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our MYGN earnings forecast. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.02). The company earned $167.30 million during the quarter, compared to analyst estimates of $164.35 million. Myriad Genetics had a negative net margin of 16.51% and a negative trailing twelve-month return on equity of 5.83%. During the same period in the prior year, the business earned ($0.19) earnings per share. What ETFs hold Myriad Genetics' stock? ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Psyk Etf (PSYK), Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has Myriad Genetics issued on next quarter's earnings? Myriad Genetics issued an update on its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of -$0.20--$0.18 for the period, compared to the consensus EPS estimate of -$0.10. The company issued revenue guidance of $170.00 million-$172.00 million, compared to the consensus revenue estimate of $174.88 million. What is Paul Diaz's approval rating as Myriad Genetics' CEO? 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS). What is Myriad Genetics' stock symbol? Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN." How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Myriad Genetics' stock price today? One share of MYGN stock can currently be purchased for approximately $23.23. How much money does Myriad Genetics make? Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.89 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. How many employees does Myriad Genetics have? The company employs 2,600 workers across the globe. Does Myriad Genetics have any subsidiaries? The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.Read More How can I contact Myriad Genetics? Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640. This page (NASDAQ:MYGN) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.